ストックスクリーナーアプリを入手
52.87
0.51%
0.27
プレマーケット:
52.60
-0.27
-0.51%
前日終値:
$52.60
開ける：
$52.43
24時間の取引高:
3.13M
Relative Volume:
1.53
時価総額：
$5.55B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.87%
1か月 パフォーマンス:
+44.85%
6か月 パフォーマンス:
+304.20%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$52.09
$52.93
1週間の範囲:
$52.09
$53.20
52週間の値動き範囲:
$12.30
$54.47
Metsera Inc Stock (MTSR) Company Profile
MTSR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
52.87 | 5.54B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | 開始されました | Leerink Partners | Outperform |
| 2025-06-20 | 開始されました | Wells Fargo | Overweight |
| 2025-02-25 | 開始されました | BofA Securities | Buy |
| 2025-02-25 | 開始されました | Evercore ISI | Outperform |
| 2025-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Metsera Inc (MTSR) 最新ニュース
IP Group notes potential income from Metsera obesity drugs - MarketScreener
IP Group shares climb 9% on potential royalties from Pfizer’s $7.3bn Metsera deal - Proactive Investors
IP Group eyes potential royalties from obesity drug - The Armchair Trader
IP Group Sees Revenue Potential From Metsera Obesity Drug Deal - DirectorsTalk Interviews
IP Group Anticipates Revenue Boost from Metsera’s Obesity Drug Development - TipRanks
IP Group eyes future royalties from obesity drug candidates following Pfizer/Metsera deal - Proactive Investors
Real time alert setup for Metsera Inc. performancePortfolio Gains Summary & Growth Focused Entry Point Reports - newser.com
Metsera (MTSR): Evaluating Valuation After a 48% One-Month Share Price Surge - Yahoo Finance
Metsera (NASDAQ:MTSR) Receives Sell (D) Rating from Weiss Ratings - MarketBeat
Metsera Inc. stock trend forecastJuly 2025 Action & Smart Allocation Stock Tips - newser.com
How to integrate Metsera Inc. into portfolio analysis toolsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Pfizer Aims To Close Gap On Obesity Drugs With Metsera 09/23/2025 - MediaPost
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders - The Malaysian Reserve
Novo Nordisk’s liver deal misses bigger ailment - Reuters
What data driven models say about Metsera Inc.’s futureJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Does Metsera Inc. show high probability of reboundSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Metsera Inc. stock near bottom after declineJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Will Metsera Inc. rebound enough to break even2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
Applying Elliott Wave Theory to Metsera Inc.Weekly Stock Analysis & Technical Pattern Based Signals - newser.com
Pfizer: Mastering The Art Of The Deal With MetseraUpgraded To Buy (NYSE:PFE) - Seeking Alpha
Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inside INdiana Business - FinancialContent
Down 50%, Should You Buy the Dip on Pfizer? - The Motley Fool
Is this a good reentry point in Metsera Inc.Exit Point & Consistent Return Investment Signals - newser.com
Is Metsera Inc. stock poised for growthWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Will earnings trigger a reversal in Metsera Inc.July 2025 PostEarnings & Verified Trade Idea Suggestions - newser.com
Is Metsera Inc. stock resilient to inflationJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles - MSN
Where Metsera’s data fit in the obesity landscape - BioCentury
Will Metsera Inc. stock split again soonWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
Metsera (NASDAQ:MTSR) Raised to "Hold" at Wall Street Zen - MarketBeat
Metsera’s Phase IIb GLP-1 Data Show Competitive Efficacy, Tolerability - insights.citeline.com
Metsera strengthens case for Pfizer buyout with latest study data - BioPharma Dive
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial - inkl
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 b - The Economic Times
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisition - MSN
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer. - Barron's
Pfizer M&A prospect Metsera heads to phase III with lead GLP-1 - BioWorld MedTech
Trump’s MFN deadline came and went - statnews.com
Metsera’s Obesity Drug Shows 'Very Encouraging' Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet - BioSpace
Metsera (NASDAQ:MTSR) Cut to Equal Weight at Wells Fargo & Company - MarketBeat
Pfizer licking its lips as Metsera presents positive weight loss data - The Pharma Letter
Wells Fargo Downgrades Metsera to Equal Weight From Overweight, Cuts Price Target to $54 From $65 - MarketScreener
Metsera’s new obesity data mean Pfizer has side effect and efficacy questions to answer - Endpoints News
Metsera Inc (MTSR) 財務データ
Metsera Inc (MTSR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Metsera Inc (MTSR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Burow Kristina | Director |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
5.74%
大文字化:
|
ボリューム (24 時間):